Frequency of Extrapyramidal Adverse Reactions in Schizophrenic Outpatients Treated with Risperidone, Olanzapine, Quetiapine or Haloperidol : Results of the EIRE Study

Clinical Drug Investigation
J BobesG Hernández

Abstract

The EIRE (Estudio de Investigaciön de Resultados en Esquizofrenia - Outcomes Research Study in Schizophrenia) study was initiated in order to assess the frequency of adverse reactions [extrapyramidal symptoms (EPS), hyperprolactinaemia, sexual dysfunction and weight gain] caused by atypical antipsychotics and haloperidol in patients with schizophrenia during routine treatment in clinical practice. This paper presents the results of the assessment of extrapyramidal adverse reactions. Outpatients diagnosed with schizophrenia according to the Diagnostic and Statistical Manual of mental disorders, 4th edition (DSM-IV), criteria and receiving a single antipsychotic (risperidone, olanzapine, quetiapine or haloperidol) for at least 4 weeks were consecutively recruited. In this cross-sectional and non-interventional study data were collected in a single visit; this included demographic and clinical characteristics, current antipsychotic and concomitant treatment, and data on several adverse effects listed in a modified version of the UKU (Udvalg for Kliniske Undersogelser - Committee on Clinical Investigations) scale. For paired comparisons of the frequency of adverse reactions between treatments the Chi-squared (χ2) test was used. For...Continue Reading

References

Jan 1, 1992·Social Psychiatry and Psychiatric Epidemiology·R G McCreadie
Nov 6, 1991·JAMA : the Journal of the American Medical Association·B L SaltzK Kahaner
Oct 1, 1990·Archives of General Psychiatry·S K HogeE Kaplan
Aug 1, 1990·Archives of General Psychiatry·D F LevinsonP Silver
Aug 1, 1988·The American Journal of Psychiatry·G W AranaG A Keepers
Jul 1, 1974·Archives of General Psychiatry·T Van Putten
Jun 1, 1994·The American Journal of Psychiatry·S R Marder, R C Meibach
Jan 1, 1996·Acta Psychiatrica Scandinavica. Supplementum·N A Keks
Oct 1, 1998·Pharmacopsychiatry·M JaussC Mundt
Oct 30, 1998·Journal of Psychiatric Research·D V JesteM P Caligiuri
Oct 30, 1998·Journal of Psychiatric Research·M D Jibson, R Tandon
Nov 13, 1998·The American Journal of Psychiatry·M G WoernerJ M Kane
Oct 3, 1999·Journal of Clinical Psychopharmacology·W W Fleischhacker, M Hummer
Dec 1, 2000·BMJ : British Medical Journal·S Kapur, G Remington
Oct 5, 2001·Expert Opinion on Pharmacotherapy·P E KeckL M Arnold
Sep 16, 2003·Drugs of Today·J M Goldstein

❮ Previous
Next ❯

Citations

Mar 20, 2003·Pharmacoepidemiology and Drug Safety
Jan 23, 2009·The Cochrane Database of Systematic Reviews·Adib EssaliJohn Rathbone
Aug 16, 2017·Health Technology Assessment : HTA·Hanna BergmanClive E Adams
Mar 1, 2005·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Joseph M Pierre
Oct 2, 2021·The Senior Care Pharmacist·Sharon SeeMartine Sanon

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.